Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.

Pipeline

CORE NEUROLOGY PIPELINE
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Commentary
Chronic Neuropathic Pain (Nav 1.7)	Data presented at ASGCT 23			None	Nav 1.7 IND-enabling activities continue to advance
Prion Disease	Data presented at ASGCT 24			None	Prion CTA-enabling activities continue to advance
Tauopathies	Data presented at ASGCT 24			Genentech	August 2024: Announced epigenetic regulation and capsid delivery license agreement with Genentech
Undisclosed				Genentech	August 2024: Announced epigenetic regulation and capsid delivery license agreement with Genentech
ALS/FTD	Data presented at ASGCT 24			Alexion	None
Huntington's Disease				Takeda	None

OTHER PROGRAMS
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Commentary
Hemophilia A (Giroctogene fitelparvovec)	Data presented at ASH 2023			Pfizer	July 2024: Positive topline readout in Phase 3 AFFINE trial. Pfizer plans to discuss data with regulatory authorities in coming months.
Fabry Disease (Isaralgagene civaparvovec)	Data presented at WORLDSymposium 2024			None	Continue to amass encouraging clinical data. Potential partnership discussions ongoing.

Clinical Programs

Learn more about our Clinical Programs.

Clinical Trials

Learn more about our approach to clinical trials.

Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners.

View Clinical Trials

Collaborations

We seek collaborations that can extend or complement our leading genomic medicine capabilities

Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.

Our Partners

Sangamo and Alexion are collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

Chroma Medicine has a research evaluation, option and license agreement with Sangamo to explore zinc finger proteins (ZFPs) for epigenetic editing in specified targets outside of the central nervous system.

Sangamo has a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases, focused on the tau gene, which is critically involved in Alzheimer’s disease and other tauopathies, as well as a second undisclosed neurology target.

Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia A.

Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, has a research evaluation and option agreement with Sangamo to evaluate certain proprietary novel engineered cerebrospinal fluid-administered capsids with enhanced nervous system delivery, generated through Sangamo’s capsid engineering platform, SIFTER.

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.

Interested in collaborating with us?

Contact Stephanie Seiler, Head of Business Development and Alliance Management

Contact Stephanie

Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Sangamo is using groundbreaking science and novel technology to replace today’s symptomatic treatments with tomorrow’s genomic cures.